A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)
Clinical trial NCT02752074 · COMPLETED
Trial details
- NCT number
- NCT02752074
- Sponsor
- Incyte Corporation
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-06-21
- Primary completion
- 2018-01-08
- Enrollment
- 706
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.